The Swedish molecular diagnostics firm will use the proceeds, in part, to fund the planned launch of its Immray PanCan-d assay for detecting pancreatic cancer.
Over the next three years, Immunovia and its partners will use the firm's Immray PanCan-d assay to screen 6,000 diabetes patients for pancreatic cancer.
The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.
SMiLE-seq combines antibody arrays, mechanical trapping, and next-generation sequencing readouts to provide a new platform for characterizing DNA-protein interactions.
The study, called Panfam-1, will analyze 1,000 individuals at high risk of familial pancreatic cancer over three years using the company's antibody array test.
Translational scientist Jacqueline Achkar of Albert Einstein Medical College will lead several collaborations to build a point-of-care diagnostic platform.
The firm is developing tests based on its microarray technology, which is capable of printing multiple types of biomarkers.
The Swedish firm, a spinout of Lund University, will evaluate the array-based blood tests to confirm, rule out, and monitor the autoimmune disease.
The microcapillary-based single-cell platform is designed to analyze antibodies but could be used to detect other cell products.
ImmunArray is launching the SLE-Key Rule Out test to exclude a diagnosis of lupus, a test run on its multiple-antigen microarray-based technology.
Researchers describe a way to share data while keeping it secure, Agence France Presse reports.
In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.
India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.
A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.